Method and system for monitoring renal function change in mouse hepatorenal syndrome model

Abstract

The invention discloses a method and a system for monitoring renal function changes in a mouse hepatorenal syndrome model. The method comprises the following steps: injecting an FITC-Sinimine solution; the method comprises the following steps of: exciting and acquiring a fluorescence signal emitted by FITC-Sinurin after the FITC-Sinurin is subjected to exciting light in real time by using a detection device, and then processing the fluorescence signal; the method comprises the following steps: performing real-time calculation, generating a fluorescence decay curve, fitting the clearance rate of FITC-Sinistrin in the kidney, calculating GFR, and generating a GFR change map which is visual along with time points. According to the method, the FITC-Sinistrin is used as a kidney specific fluorescent marker and is combined with a percutaneous non-invasive fluorescence detection technology, and the fluorescence decay is tracked in real time, so that the renal function change level of the HRS mouse is reflected, a dynamic renal function monitoring scheme adaptive to a mouse model is provided, and technical support is provided for pathological mechanism research and drug screening of the HRS.

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a method and system for monitoring renal function changes in a mouse hepatorenal syndrome model. Background Art

[0002] Hepatorenal syndrome (HRS) is one of the most serious complications of decompensated cirrhosis. Its pathophysiological mechanism is closely related to visceral vasodilation, inadequate effective arterial blood volume, and renal vasoconstriction. HRS has a high incidence and mortality rate, and is characterized by a sharp decline in renal function. According to a large-scale clinical study in 2020, the incidence of HRS in patients with cirrhosis reached 8.3%, and the 3-month mortality rate of patients with type 1 HRS was as high as 80%. HRS currently lacks effective treatment, and liver transplantation is the only definite cure, but it is limited by donor shortages and the risk of perioperative deterioration of renal function. Currently, there is little basic research on HRS, and the difficulty lies in monitoring renal function in HRS animal models.

[0003] Currently, the establishment of HRS animal models for basic research still relies on the detection of blood creatinine (SCr) and blood urea nitrogen (BUN) or urine collection and analysis (such as the total urine volume and the levels of urine sodium and creatinine in urine components). The following problems still need to be solved:

[0004] 1) Invasive: Blood sampling from the orbital venous plexus of mice for SCr and BUN testing can easily lead to a decrease in the mouse's total volume (approximately 2 ml / 20 g). Furthermore, frequent blood sampling can exacerbate renal hypoperfusion, affecting model stability, and can cause stress and even death in mice, leading to experimental failure. Studies have shown that a single blood sampling can reduce renal blood flow in mice by 15%, and repeated blood sampling can even affect glomerular filtration rate (GFR) measurements.

[0005] 2) Non-continuity: Renal function deteriorates nonlinearly during the course of HRS. HRS patients often experience a sharp decline in renal function within a short period of time. However, traditional methods can only obtain renal function levels at a single time point, and existing technologies cannot capture the dynamic attenuation curve of GFR, making it impossible to continuously and dynamically monitor renal function changes.

[0006] 3) Lag: Currently, the establishment of the HRS model relies on the test results of blood and urine samples. However, in practice, since blood and urine samples need to complete the testing process in the laboratory (sample centrifugation → supernatant separation → biochemical analysis), which takes more than 1-2 hours to obtain test results, the test results often have a lag and cannot actually reflect the level of renal function. Therefore, this method cannot achieve early warning.

[0007] 4) Sensitivity Deficit: Mice have a high baseline GFR of 0.8-1.3 mL / min and low serum creatinine levels. However, traditional detection methods lack the ability to discern changes in GFR below 10% (<0.1 mL / min), making it difficult to identify and diagnose HRS early. Studies have found that serum creatinine in mice only rises significantly when 50% of their nephrons are lost, often leading to missed diagnoses of HRS in the early stages.

[0008] Among the above-mentioned existing technologies, most are designed based on clinical needs and do not fully consider the special needs of small animal models (such as non-invasiveness and repeated testing). In addition, the pathophysiological complexity of HRS makes it difficult to fully assess renal function using a single indicator (such as creatinine), and the development of multimodal dynamic monitoring technology lags behind the needs of basic research. In view of this, a non-invasive, real-time dynamic monitoring, highly sensitive, and practical detection technology is needed to establish a mouse HRS model. Summary of the Invention

[0009] In order to overcome the deficiencies of the prior art, one of the purposes of the present invention is to provide a method for monitoring changes in renal function in a mouse hepatorenal syndrome model, aiming to address the technical difficulty of lacking non-invasive, dynamic, and real-time monitoring of mouse renal function in hepatorenal syndrome (HRS) research. Specifically, the prior art relies on invasive plasma or urine detection methods, which cannot achieve continuous, dynamic, real-time, non-invasive, and sensitive renal function assessment in mouse models, and the existing fluorescence monitoring technology is not optimized for the weak signal on the mouse body surface. The method of the present invention combines FITC-Sinistrin as a kidney-specific fluorescent marker with transcutaneous non-invasive fluorescence detection technology to provide a dynamic renal function monitoring scheme adapted to the mouse model, providing technical support for the study of the pathological mechanism of HRS and drug screening.

[0010] The second purpose of the present invention is to provide a system for monitoring changes in renal function in a mouse hepatorenal syndrome model, which is used to detect the renal function of the HRS mouse model by detecting fluorescence intensity on the body surface, thereby realizing continuous, dynamic, real-time, non-invasive and sensitive renal function assessment.

[0011] One of the objectives of the present invention is achieved by the following technical solution:

[0012] A method for monitoring changes in renal function in a mouse hepatorenal syndrome model comprises the following steps:

[0013] S1: FITC-Sinistrin solution (FITC-Sinistrin is a polysaccharide labeled with fluorescein isothiocyanate) was injected into the tail vein of the mouse;

[0014] S2: Using a transcutaneous fluorescence detection device, FITC-sinistrin in mice is stimulated and the fluorescence signal emitted by FITC-sinitrin after being stimulated by the light is collected in real time. The fluorescence signal is then filtered, amplified, baseline corrected, and digitized. The processed signal is then converted into an electrical signal for external output.

[0015] S3: Receive the electrical signal emitted by the transcutaneous surface fluorescence detection device, perform real-time calculations based on the electrical signal, generate a fluorescence decay curve, fit the clearance rate of FITC-Sinistrin in the kidney, calculate the GFR based on the clearance rate, and generate a visual GFR change map over time.

[0016] Furthermore, in step S1, the dosage of the FITC-Sinistrin solution is 60 mg / kg-80 mg / kg, and the solvent is 0.8-1.0 wt% normal saline.

[0017] Furthermore, in step S1, the polysaccharide contained in the FITC-Sinistrin solution is one or more of dextran and chitosan.

[0018] Furthermore, in step S2, the transcutaneous body surface fluorescence detection device includes a fluorescence signal excitation module, a fluorescence signal receiving module, a signal processing module and a signal transmission module. The fluorescence signal excitation module is used to emit excitation light to excite FITC-Sinitrin through the mouse skin; the fluorescence signal receiving module is used to detect the fluorescence signal emitted by FITC-Sinitrin after being exposed to the excitation light; the signal processing module is used to filter, amplify, correct the baseline and digitize the received fluorescence signal; the signal transmission module is used to convert the processed signal into an electrical signal and output it to the outside.

[0019] Furthermore, the wavelength of the excitation light is 488 nm; and the emission wavelength of the fluorescence signal is 520 nm.

[0020] Furthermore, in step S3, the calculation formula of GFR is:

[0021]

[0022] T1 / 2 is the half-life of FITC-Sinistrin.

[0023] The second object of the present invention is achieved by the following technical solution:

[0024] A system for monitoring changes in renal function in a mouse hepatorenal syndrome model, comprising:

[0025] Injection module, used to inject FITC-Sinistrin solution into the tail vein of mice;

[0026] The body surface fluorescence detection module is used to stimulate FITC-Sinistrin in mice using a transcutaneous body surface fluorescence detection device and collect in real time the fluorescence signal emitted by FITC-Sinitrin after being excited by the light. The fluorescence signal is then filtered, amplified, baseline corrected, and digitized, and the processed signal is converted into an electrical signal for external output.

[0027] The data analysis module is used to receive the electrical signals emitted by the transcutaneous surface fluorescence detection device, perform real-time calculations based on the electrical signals, generate a fluorescence decay curve, fit the clearance rate of FITC-Sinistrin in the kidney, calculate the GFR based on the clearance rate, and generate a visual GFR change graph over time.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] 1. The method of the present invention combines FITC-sinistrin as a kidney-specific fluorescent marker with transcutaneous non-invasive fluorescence detection technology. Using a transcutaneous surface fluorescence detection device, the fluorescence decay is tracked in real time, thereby reflecting the level of renal function changes in HRS mice. This method provides a dynamic renal function monitoring solution adapted to the mouse model, providing technical support for the study of the pathological mechanism of HRS and drug screening. The present invention is particularly adapted to the HRS mouse model and solves the problems of traditional methods in detecting renal function, such as invasiveness, discontinuity, lack of dynamic and real-time detection, and low sensitivity.

[0030] 2. FITC-Sinistrin (a polysaccharide labeled with fluorescein isothiocyanate) in the present invention has a molecular weight close to that of inulin (a gold marker reflecting glomerular filtration), and can be freely filtered in the glomerulus without being reabsorbed, making it a potential new substance for measuring glomerular filtration rate. In addition, since the polysaccharide is labeled with FITC, a commonly used fluorescent channel, renal function can be reflected by detecting the fluorescence intensity and the strength of the fluorescence signal attenuation. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Schematic diagram of the process of the method for monitoring renal function changes in a mouse hepatorenal syndrome model of the present invention;

[0032] Figure 2 Schematic diagram of the method of the present invention after using a skin preparation knife to prepare the skin on the back of a mouse;

[0033] Figure 3 This is a schematic diagram of the structure of placing a fluorescence detection device at the skin preparation site in the method of the present invention;

[0034] Figure 4This is a schematic diagram of the structure of using medical tape to fix the fluorescence detection device in the method of the present invention;

[0035] Figure 5 is the original fluorescence attenuation curve after the body surface receives the fluorescence signal in the method of the present invention;

[0036] Figure 6 is the fluorescence decay curve at different time points after HRS model;

[0037] Figure 7 This is a comparison chart of GFR values ​​at different time points calculated based on the fluorescence decay signal;

[0038] Figure 8 The normalized fluorescence decay curve is shown in Figure 2. DETAILED DESCRIPTION

[0039] Disadvantages and shortcomings of existing technologies:

[0040] 1. Invasiveness and operational complexity: Traditional blood tests require repeated punctures for blood collection, which is cumbersome and subject to ethical restrictions. Furthermore, due to the limited circulating blood volume of mice, repeated blood collection and frequent operations often cause stress and model instability in mice, and in severe cases, lead to death. Urine sample testing often requires the use of metabolic cages for urine collection and testing, which is expensive and difficult to operate, and urine sample collection is often difficult.

[0041] 2. Insufficient sensitivity and accuracy: In patients with end-stage liver disease and HRS mouse models, cachexia leads to muscle wasting or malnutrition, resulting in inaccurate measurement of blood creatinine, making it often difficult to respond to renal function decline early. In addition, mice have low baseline creatinine levels and high glomerular filtration rates. Mild renal damage does not result in obvious changes in creatinine, while changes in creatinine in moderate to severe renal damage can only be detected by current laboratory tests. This often leads to limited recognition of early renal function changes in HRS and affects the early diagnosis and treatment of the disease. Renal blood flow ultrasound Doppler has high technical requirements for the operator, cannot directly quantify GFR, and is easily interfered by hemodynamic fluctuations.

[0042] 3. Lack of dynamic monitoring capabilities: Currently, renal function tests in HRS mouse models are mostly performed at a single time point, and traditional blood renal function tests often have a lag due to technical reasons. They cannot continuously, in real time, and dynamically detect changes in renal function, making it difficult to evaluate the immediate effects of therapeutic interventions.

[0043] In view of the shortcomings and deficiencies of the above-mentioned prior art, the following method for monitoring renal function changes in a mouse hepatorenal syndrome model was designed, such as Figure 1 As shown, the method includes the following steps:

[0044] S1: Installation of body surface fluorescence detection device

[0045] After shaving an area of ​​approximately 2×2 cm on the mouse's back, use medical tape to gently attach the small surface fluorescence detection device to the mouse's exposed skin.

[0046] The small-scale surface fluorescence detection device includes a fluorescence signal excitation module, a fluorescence signal receiving module, a signal processing module, and a signal transmitting module. The fluorescence signal excitation module is used to emit excitation light to excite FITC-Sinitrin through the mouse skin; the fluorescence signal receiving module is used to detect the fluorescence signal emitted by FITC-Sinitrin after being exposed to the excitation light; the signal processing module is used to filter, amplify, correct the baseline, and digitize the received fluorescence signal; and the signal transmitting module is used to convert the processed signal into an electrical signal for external output. In one embodiment, the wavelength of the excitation light is 488nm; the emission wavelength of the fluorescence signal is 520nm. In other embodiments, the wavelength of the excitation light and the emission wavelength of the fluorescence signal can be selected from other wavelengths according to different needs and equipment, which will not be repeated here.

[0047] S2: FITC-Sinistrin Injection

[0048] FITC-Sinitrin solution was injected into the mouse tail vein; after injection, FITC-Sinistrin reached the kidneys through the blood circulation, where it was freely filtered and not reabsorbed.

[0049] The dosage of the FITC-Sinistrin solution is 60 mg / kg-80 mg / kg, and the solvent is 0.8-1.0 wt% normal saline. Preferably, the dosage is 75 mg / kg, and the solvent is 0.9 wt% normal saline. The polysaccharide contained in the FITC-Sinistrin solution is one or more of dextran and chitosan.

[0050] S3: Signal Detection

[0051] A transcutaneous fluorescence detection device was used to excite FITC-Sinistrin in mice, and the fluorescence signal emitted by FITC-Sinitrin after being excited by the light was collected in real time. The fluorescence signal was then filtered, amplified, baseline corrected, and digitized, and then converted into an electrical signal for external output.

[0052] In this step, the device has a built-in chip, which excites and detects the fluorescent signal through the fluorescent signal excitation module, fluorescent signal receiving module, signal processing module and signal transmission module in the chip, and performs filtering, amplification, baseline correction and digital processing. The signal is then converted into an electrical signal and transmitted to a computer for the next step of processing.

[0053] S4: Data processing and analysis

[0054] The system receives electrical signals emitted by a transcutaneous surface fluorescence detection device, performs real-time calculations based on the electrical signals, generates a fluorescence decay curve, fits the clearance rate of FITC-Sinistrin in the kidney, calculates GFR based on the clearance rate, and generates a visual graph of GFR changes over time.

[0055] The calculation formula for GFR is:

[0056]

[0057] T1 / 2 is the half-life of FITC-Sinistrin.

[0058] In other embodiments, the present invention further provides a system for monitoring changes in renal function in a mouse hepatorenal syndrome model, comprising:

[0059] Injection module, used to inject FITC-Sinistrin solution into the tail vein of mice;

[0060] The body surface fluorescence detection module is used to stimulate FITC-Sinistrin in mice using a transcutaneous body surface fluorescence detection device and collect in real time the fluorescence signal emitted by FITC-Sinitrin after being excited by the light. The fluorescence signal is then converted, filtered, amplified, baseline corrected, and digitized, and the processed electrical signal is then outputted.

[0061] The data analysis module is used to receive the electrical signals emitted by the transcutaneous surface fluorescence detection device, perform real-time calculations based on the electrical signals, generate a fluorescence decay curve, fit the clearance rate of FITC-Sinistrin in the kidney, calculate the GFR based on the clearance rate, and generate a visual GFR change graph over time.

[0062] The above methods and systems address the core shortcomings of existing technologies by integrating FITC-Sinistrin markers, non-invasive surface fluorescence detection technology, and mouse model adaptation and optimization. The specific beneficial effects and corresponding technical means are as follows:

[0063] (1) Non-invasive and dynamic monitoring of renal function: no blood or urine collection is required, which reduces animal stress and avoids experimental interference; it continuously tracks changes in renal function in real time, and compared with traditional invasive detection methods, it can capture the dynamic changes of GFR in the course of HRS at an early stage; by stimulating the surface fluorescence signal with an excitation light source (488nm), the metabolic decay of FITC-Sinistrin in the mouse kidney is directly detected through the skin, without the need for invasive sampling such as orbital blood sampling or bladder puncture to obtain urine; the fluorescence intensity is collected every 10 seconds (for more than 120 minutes), and a continuous decay curve can be generated to achieve dynamic and continuous observation of renal function changes; it breaks through the limitations of traditional single time point detection;

[0064] (2) Highly sensitive detection adapted to the HRS mouse model: In the HRS model, serum creatinine (SCr) and blood urea nitrogen (BUN) levels are often low due to cachexia or low baseline levels, which can lead to the inability to identify HRS early. FITC-Sinistrin directly reflects changes in GFR and is more sensitive than traditional detection methods.

[0065] Even when the fluorescence signal from the mouse's surface is weak (due to its small size and obstruction by hair), a high signal-to-noise ratio can still be achieved. Adaptive filtering technology is used to eliminate background noise (such as ambient light and skin autofluorescence). The hair on the mouse's back is shaved (2 × 2 cm), and the detection device is fixed with medical tape to reduce motion artifacts and signal interference.

[0066] (3) Dynamic monitoring and immediate feedback: Generate GFR change maps in real time to dynamically evaluate the immediate effects of therapeutic interventions (such as drugs), avoiding the lag of traditional testing (which requires centrifugation, testing, etc.); in addition, continuous monitoring of changes in renal function levels reveals the dynamic patterns of renal function changes, facilitating early identification and diagnosis of HRS; real-time display of fluorescence intensity curves and GFR values ​​provides intuitive feedback on disease progression;

[0067] (4) Technical scalability and standardized operation: Adaptable to a variety of renal disease models, such as acute kidney injury (AKI), diabetic nephropathy, and septic nephropathy, only requiring adjustment of marker doses or detection parameters; standardized operation procedures: parameters such as injection dose and detection time have been experimentally verified, and the results are reproducible and can be flexibly adapted to different experimental scenarios;

[0068] (5) Reduce experimental costs and ethical risks: Avoid stress or hemorrhagic shock in mice caused by frequent blood sampling; no metabolic cages or expensive laboratory equipment are required, which reduces laboratory operating costs and eliminates tedious steps such as blood centrifugation and urine collection. In addition, the portable design reduces the space occupied by the equipment and is suitable for small animal laboratories.

[0069] The synergistic effect of these technical means gives the present invention significant preclinical research value in the study of hepatorenal syndrome and provides a general technical framework for non-invasive monitoring of animal models of kidney disease.

[0070] The present invention will be further described below in conjunction with specific implementation methods. It should be noted that, under the premise of no conflict, the various embodiments or technical features described below can be arbitrarily combined to form new embodiments.

[0071] Unless otherwise specified, the experimental methods in the following examples are conventional methods and were performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials and reagents used in the following examples, unless otherwise specified, were all commercially available.

[0072] Example 1 Preparation of mice

[0073] Use a skin preparation knife to prepare the skin on the back of the mouse, with an area of ​​about 2 × 2 cm. Figure 2 shown.

[0074] Example 2 Installation of Body Surface Fluorescence Detection Device

[0075] like Figure 3 As shown, place the micro-mouse-adapted fluorescence detection device on the prepared skin of the mouse, as shown in Figure 4 As shown, medical tape was used to adhere and fix the fluorescence detection device so that the fluorescence detection device was gently adhered to the exposed skin of the mouse.

[0076] Example 3 FITC-Sinistrin injection

[0077] The mouse was fixed on a special tail vein syringe, the tail vein was exposed, and 100 μl of FITC-Sinistrin solution (75 mg / kg, solvent is 0.9% saline) was slowly injected into the tail vein using an insulin needle; after injection, FITC-Sinistrin reached the kidneys through the blood circulation, where it was freely filtered and not reabsorbed.

[0078] Example 4 Signal Acquisition

[0079] Immediately after injection, the surface fluorescence detection device was activated. The excitation light module irradiated the mouse's back or abdominal skin to stimulate FITC-sinistrin to emit fluorescence. The fluorescence receiving module was set to collect the fluorescence signal every 10 seconds for 120 minutes.

[0080] The signal processing module filters the original fluorescence signal, removes background noise, corrects the baseline value of the fluorescence signal, converts the filtered signal into a digital signal, and transmits it to the data analysis module;

[0081] Example 5 Data Analysis and Processing

[0082] The data analysis module fits the fluorescence decay curve and calculates the half-life (T1 / 2) of FITC-Sinistrin, wherein the half-life of FITC-Sinistrin is further used to calculate GFR, and the formula is as follows:

[0083]

[0084] T1 / 2 is the half-life of FITC-Sinistrin.

[0085] Example 6 Result Output

[0086] Generate a fluorescence decay curve and GFR value, and visualize the current fluorescence intensity and GFR change trend through a standardized curve.

[0087] Compare the following monitoring of reduced renal function with traditional renal function indicators:

[0088] 1. Original fluorescence decay curve

[0089] The fluorescence attenuation curve after the fluorescence signal is received by the body surface is converted into a digital signal (automatically calculate the glomerular filtration function), such as Figure 5 shown.

[0090] 2. Fluorescence decay curves of the normal group and HRS mouse model group at different time points

[0091] Set up control group: Sham;

[0092] Liver fibrosis group: CCl4+PBS;

[0093] Set up the HRS group: CCl4+LPS.

[0094] The fluorescence attenuation signal and GFR level at 0h, 2h, 4h, 8h and 12h of HRS model were detected respectively. The test results are as follows Figure 6 and Figure 7 The fluorescence intensity decay curves and GFR values ​​of the HRS model at different time points are shown, where Figure 6 is the fluorescence decay curve at different time points after HRS model; Figure 7 This is a comparison chart of GFR values ​​at different time points calculated based on the fluorescence decay signal.

[0095] 3. Standard visualization of fluorescence decay curve and comparison with traditional renal function test indicators, such as Figure 8 As shown in Table 1.

[0096] Table 1 Comparison of traditional renal function indicators and surface fluorescence detection (tGFR) at different time points

[0097]

[0098]

[0099] Data are Mean±SD*, compared with CCl4+PBS group; *, p<0.05; **, p<0.01.

[0100] It can be seen from the comparison that the method of the present invention can monitor the changes in renal function in the mouse hepatorenal syndrome model.

[0101] The above embodiments are only preferred embodiments of the present invention and cannot be used to limit the scope of protection of the present invention. Any non-substantial changes and replacements made by technicians in this field on the basis of the present invention fall within the scope of protection required by the present invention.

Claims

1. A method for monitoring changes in renal function in a mouse hepatorenal syndrome model, characterized in that: The steps include: S1: FITC-Sinistrin solution was injected into the tail vein of mice; S2: Using a transcutaneous fluorescence detection device, FITC-sinistrin in mice is stimulated and the fluorescence signal emitted by FITC-sinitrin after being stimulated by the light is collected in real time. The fluorescence signal is then filtered, amplified, baseline corrected, and digitized. The processed signal is then converted into an electrical signal for external output. S3: Receive the electrical signal emitted by the transcutaneous surface fluorescence detection device, perform real-time calculations based on the electrical signal, generate a fluorescence decay curve, fit the clearance rate of FITC-Sinistrin in the kidney, calculate the GFR based on the clearance rate, and generate a visual GFR change map over time.

2. The method for monitoring renal function changes in a mouse hepatorenal syndrome model according to claim 1, wherein In step S1 , the dosage of the FITC-Sinistrin solution is 60 mg / kg-80 mg / kg, and the solvent is 0.8-1.0 wt % normal saline.

3. The method for monitoring renal function changes in a mouse hepatorenal syndrome model according to claim 2, wherein: In step S1, the polysaccharide contained in the FITC-Sinistrin solution is one or more of dextran and chitosan.

4. The method for monitoring renal function changes in a mouse hepatorenal syndrome model according to claim 1, wherein In step S2, the transcutaneous surface fluorescence detection device includes a fluorescence signal excitation module, a fluorescence signal receiving module, a signal processing module and a signal transmission module. The fluorescence signal excitation module is used to emit excitation light to excite FITC-Sinitrin through the mouse skin; the fluorescence signal receiving module is used to detect the fluorescence signal emitted by FITC-Sinitrin after being exposed to the excitation light; the signal processing module is used to filter, amplify, correct the baseline and digitize the received fluorescence signal; the signal transmission module is used to convert the processed signal into an electrical signal for external output.

5. The method for monitoring renal function changes in a mouse hepatorenal syndrome model according to claim 4, wherein: The wavelength of the excitation light is 488 nm; the emission wavelength of the fluorescence signal is 520 nm.

6. The method for monitoring renal function changes in a mouse hepatorenal syndrome model according to claim 1, wherein In step S3, the GFR is calculated as: T1 / 2 is the half-life of FITC-Sinistrin.

7. A system for monitoring changes in renal function in a mouse hepatorenal syndrome model, characterized in that: include: Injection module, used to inject FITC-Sinistrin solution into the tail vein of mice; The body surface fluorescence detection module is used to stimulate FITC-Sinistrin in mice using a transcutaneous body surface fluorescence detection device and collect in real time the fluorescence signal emitted by FITC-Sinitrin after being excited by the light. The fluorescence signal is then filtered, amplified, baseline corrected, and digitized, and the processed signal is converted into an electrical signal for external output. The data analysis module is used to receive the electrical signals emitted by the transcutaneous surface fluorescence detection device, perform real-time calculations based on the electrical signals, generate a fluorescence decay curve, fit the clearance rate of FITC-Sinistrin in the kidney, calculate the GFR based on the clearance rate, and generate a visual GFR change graph over time.

Images